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CHEMO-ENDOCRINE THERAPY FOR NEWL Y DIAGNOSED 
STAGE D2 PROSTATE CANCER 
Toshihiro SAITO， Yasuo KITAMURA and Shuichi KOMATSUBARA 
The Department 01 Urology， Niigata Cancer Center Hospital 
We evaluated 175 patients with newly diagnosed stage D2 prostate cancer who had been treated in 
our hospital between 1992 and 2003 to compare chemo幽endocrinetherapy with endocrine therapy 
alone. One hundred and thirty seven patients were treated with endocrine therapy alone. The other 
38 patients received chemo-endocrine therapy， which included medical or surgical castration 
with/without antiandrogen plus VIP (Vincristine， Ifosfamide， Peplomycin) regimen or other cytotoxic 
agents. 
The patients treated with chemo・endocrinetherapy had a significantly better prognosis than the 
patients treated with endocrine therapy alone (p<0.05)， although treatment was not randomized 
The cause-specific survival rates at 5 years for the chemo-endocrine therapy group and the endocrine 
therapy group were 6l.6% and 34.8%， respectively. These data suggest that chemo四endocrine
therapy is a potentially effective treatment for newly diagnosed stage D2 prostate cancer. 
(Hinyokika Kiyo 51 : 789-792， 2005) 























2例， CBDCA+VPI6が l例， CDDP+MTXが l
例であった.VIPレジメンは Vincristine1 mg/body 
(day 1， 2)， Ifosfamide 2 g/body (day 2-4)， Peplo-














PR 27例 (21.4%)， NC 2例(1.6%)であったのに
対し，化療あり群 (n=38)では CR31例 (81.6%)，
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Fig. 1. OveralI and cause帽specificsurvival curves 
according to treatment in 175 patients. 
疾患特異的5年生存率は34.8%であったのに対し化療






























にNationalProstatic Cancer Project (NPCP)による 3
つの randomizedtrialの報告がありト11)去勢または








半には Vandenbrouckeら， Pummerら， de Reijkeら
による randomizedstudyの報告があるが，いずれも
化学内分泌療法の明らかな優位性を示せないでい
る13-15) de R吋keらの MMCを用いた化学内分泌療
法の報告では化学療法併用群のほうが生存率が低く
QOL面でも劣っているという結果であり，化学内分
Table 1. Characteristics of 175 Stage D2 prostate cancer patients 
Chemotherapy (十)(n=38) Chemotherapy (一)(n=137) 
Age (meani:SD) 67.6i:8.1 yo 74.3土7.9yo p<O.OOI 
PS (mean土SD) 0.68土0.70 O. 72:I: 0.89 (NS) 
PSA (mean土SD) 1838.3土4611.4ng/ml 976.2土2024目ong/ml (NS) 
Tumor histology wel 7 
mod 20 69 
poor 17 59 (NS) 
EOD (mean土SD) 2.02:I: 1.17 1.7 6:I: 1. 09 (NS) 
MAB (+) 34 115 
(一) 4 20 (NS) 
EOD; extent of disease 
斎藤，ほか:前立腺癌 化学内分泌療法 791 
Table 2. Multivariate analysis of factors associated with survival in 174 patients 
Overall survival Disease-specific survival 
Factors Variables 
P-value 
Age (yo) 孟75/<75 0.665 
PS 0.1.2/3.4 0.209 
Hb (g/dl) 主12/<12 0.439 
Plt(Xl04jμ1) 孟15/<15 0.127 
ALP (IU/L) 孟500/<500 。目046
LDH (IU/L) 詮400/<400 0.067 
PSA (ng/ml) 孟100/<100 0.019 
T-stage <T3a/孟T3b 0.283 
N-stage NO/N1 0.133 
M-stage Mla/M1b.c 0.340 
EOD 0.1/2目3.4 0.252 
Tumor histology well/mod， poor 。目055
Era 1998/1999時 0.009 
CAB Yes/No 0.152 
Chemotherapy Yes/No 0.013 
EOD; extent of disease 
泌療法の評価には QOL面の検討も重要で、あると強調
されていた16)
本邦では Sakaiらや Kubotaらがretrospectivestudy 
ではあるが初期化学内分泌療法で良好な成績を報告し
ている 17，18) しかしその後に報告された本邦での

























Risk ratio (95% CI) P-value Risk ratio (95 % CI) 
0.896 (0.544-1.475) 0.184 0.679 (0.384イ 202)
1.797 (0.721-4.480) 。目313 1.677 (0.614-4.580) 
0.806 (0.466-1.393) 0.147 0.637 (0.347-1.171) 
0.649 (0.373-1.130) 0.139 0.638 (0.352-1.157) 
1.744 (1.011-3.008) 0.034 1.906 (1.052-3.454) 
1.787 (0.960-3.329) 0.236 1.522 (0.760-3.045) 
0.523 (0.304-0.900) 0.016 0.478 (0.261-0.873) 
。目762(0.464-1.251) 0.023 0.536 (0.313-0.918) 
0.663 (0.388-1.133) 0.295 0.724 (0.396-1.324) 
1.549 (0.631-3.805) 0.288 1.719 (0.633-4.668) 
0.701 (0.382-1.286) 0.120 0.580 (0.292-1.152) 
2.954 (0.979-8.917) 0.140 2.359 (0.754叩 7.380)
1.905 (1.l78-3.080) 0.011 1.990 (1.168-3.389) 
0.648 (0.358-1.174) 0.038 0却 7(0.257-0.962) 
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